
A recent study, analyzing data from 1348 patients across 3326.2 patient-years in the phase 2b/3 SELECTION study and its ongoing extension SELECTIONLTE, reveals that Filgotinib is well-tolerated and safe for adults with moderately to severely active ulcerative colitis (UC). The safety analysis, which included age and biological exposure subgroups, showed no unexpected safety concerns. While there was a slightly higher incidence of herpes zoster with Filgotinib, it was generally well-tolerated. The study supports the safety and effectiveness of Filgotinib in UC treatment.
Like
Save
Share